Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

Altered pharmacokinetics of antibody drugs has been reported in advanced gastric cancer (AGC). We aim to evaluate bevacizumab pharmacokinetics in AGC from the Phase III trial (AVAGAST), and explore the influence of patient variables. Bevacizumab concentrations (Cp) were measured in plasma samples ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Kelong, Jin, Jin, Maia, Mauricio, Lowe, John, Sersch, Martina A., Allison, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147052/
https://www.ncbi.nlm.nih.gov/pubmed/24942210
http://dx.doi.org/10.1208/s12248-014-9631-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147052/
https://www.ncbi.nlm.nih.gov/pubmed/24942210
http://dx.doi.org/10.1208/s12248-014-9631-6

Ejemplares similares